roche holding ag - RHHVF

RHHVF

Close Chg Chg %
457.00 3.30 0.72%

Closed Market

460.30

+3.30 (0.72%)

Volume: 37.69K

Last Updated:

Feb 6, 2026, 3:53 PM EDT

Company Overview: roche holding ag - RHHVF

RHHVF Key Data

Open

$447.22

Day Range

447.22 - 465.00

52 Week Range

277.00 - 478.81

Market Cap

N/A

Shares Outstanding

NaN

Public Float

688.93M

Beta

N/A

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

N/A

Yield

N/A

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

18.65K

 

RHHVF Performance

1 Week
 
3.13%
 
1 Month
 
8.42%
 
3 Months
 
36.14%
 
1 Year
 
45.81%
 
5 Years
 
32.73%
 

RHHVF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 22
Full Ratings ➔
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Roche Holding Ag - RHHVF

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
66.26B 65.34B 68.69B 74.07B
Sales Growth
-3.54% -1.39% +5.13% +7.83%
Cost of Goods Sold (COGS) incl D&A
19.72B 17.60B 18.20B 19.60B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
4.00B 3.87B 3.89B 4.09B
Depreciation
3.02B 3.07B 3.05B 3.27B
Amortization of Intangibles
982.13M 796.75M 842.54M 813.98M
COGS Growth
-8.48% -10.76% +3.38% +7.73%
Gross Income
46.54B 47.74B 50.49B 54.47B
Gross Income Growth
-1.28% +2.58% +5.78% +7.87%
Gross Profit Margin
+70.23% +73.06% +73.51% +73.53%
2022 2023 2024 2025 5-year trend
SG&A Expense
27.30B 29.31B 29.52B 31.01B
Research & Development
14.71B 14.72B 14.26B 14.69B
Other SG&A
12.59B 14.59B 15.26B 16.33B
SGA Growth
-2.40% +7.35% +0.70% +5.08%
Other Operating Expense
201.03M 233.68M 275.93M 258.88M
Unusual Expense
4.59B 3.55B 7.98B 4.02B
EBIT after Unusual Expense
14.44B 14.65B 12.73B 19.17B
Non Operating Income/Expense
3.33B 1.98B 2.13B 2.69B
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
636.61M 921.38M 1.42B 1.43B
Interest Expense Growth
+70.68% +44.73% +53.80% +0.86%
Gross Interest Expense
636.61M 921.38M 1.42B 1.43B
Interest Capitalized
- - - -
-
Pretax Income
17.14B 15.70B 13.44B 20.44B
Pretax Income Growth
-9.95% -8.38% -14.39% +52.05%
Pretax Margin
+25.87% +24.03% +19.57% +27.59%
Income Tax
2.93B 1.92B 2.96B 3.82B
Income Tax - Current - Domestic
4.66B 3.15B 4.91B 4.06B
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(1.74B) (1.24B) (1.95B) (236.01M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
14.17B 13.75B 10.43B 16.62B
Minority Interest Expense
1.16B 956.99M 1.03B 1.11B
Net Income
13.01B 12.79B 9.40B 15.51B
Net Income Growth
-14.64% -1.62% -26.54% +65.01%
Net Margin Growth
+19.63% +19.58% +13.68% +20.94%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
13.01B 12.79B 9.40B 15.51B
Preferred Dividends
- - - -
-
Net Income Available to Common
13.01B 12.79B 9.40B 15.51B
EPS (Basic)
16.2567 16.0134 11.7924 19.4836
EPS (Basic) Growth
-9.31% -1.50% -26.36% +65.22%
Basic Shares Outstanding
800.00M 799.00M 797.00M 796.00M
EPS (Diluted)
16.2567 15.9138 11.7189 19.3138
EPS (Diluted) Growth
-8.23% -2.11% -26.36% +64.81%
Diluted Shares Outstanding
800.00M 804.00M 802.00M 803.00M
EBITDA
23.03B 22.06B 24.60B 27.28B
EBITDA Growth
-3.09% -4.23% +11.51% +10.91%
EBITDA Margin
+34.76% +33.76% +35.81% +36.83%

Roche Holding Ag in the News

Inside the race for a COVID-19 treatment pill

Pfizer and its rivals, including U.S.-based Merck & Co Inc and Swiss pharmaceutical Roche Holding AG are racing to produce the first antiviral pill that people could take at early signs of the illness. Their shared goal: filling a key treatment hole by helping people recently-infected with coronavirus to avoid becoming seriously ill and needing hospitalization.